SCHEMBL1045173

SCHEMBL1045173

BrCc1ccc(CBr)c(CBr)c1CBr

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049876 0.86
SCHEMBL1048345 0.82
SCHEMBL338177 0.80 GABRA1 (0.38) TRPA1ALDH1A1TSHR
SCHEMBL10933403 0.78
SCHEMBL1525361 0.76
SCHEMBL3310091 0.76 GPR84 (0.31)
SCHEMBL11427181 0.76 PNMT (0.33)
SCHEMBL7777200 0.74 TRPA1 (0.35) TRPA1ALDH1A1TSHR
SCHEMBL4158272 0.74 TRPA1 (0.35) TRPA1ALDH1A1TSHR
SCHEMBL4158266 0.74 TRPA1 (0.35) TRPA1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524989-B2 AML antigens and uses thereof KLING BIOTHERAPEUTICS B.V. (NL) 2022-12-13 US claimed
EP-3060915-A2 DETECTION OF CLEAVAGE ACTIVITY OF AN ENZYME Mologic Limited (GB) 2016-08-31 EP claimed
US-9176127-B2 Method for selecting a candidate drug compound PEPSCAN SYSTEMS B.V. (NL) 2015-11-03 US claimed
WO-2015059487-A2 DETECTION OF CLEAVAGE ACTIVITY OF AN ENZYME MOLOGIC LIMITED (GB) 2015-04-30 WO claimed
US-20140308303-A1 METHOD FOR SELECTING A CANDIDATE DRUG COMPOUND PEPSCAN SYSTEMS B.V. (NL) 2014-10-16 US claimed
US-8748105-B2 Method for selecting a candidate drug compound PEPSCAN SYSTEMS B.V. (NL) 2014-06-10 US claimed
EP-1597585-B1 METHOD FOR SELECTING A CANDIDATE DRUG COMPOUND PEPSCAN SYSTEMS BV (NL) 2011-06-15 EP claimed
US-20100322945-A1 IMMUNOGENIC COMPOUNDS AND PROTEIN MIMICS PEPSCAN SYSTEMS B.V. (NL) 2010-12-23 US claimed
EP-2052253-A2 IMMUNOGENIC COMPOUNDS AND PROTEIN MIMICS PEPSCAN SYSTEMS B.V. (NL) 2009-04-29 EP claimed
US-20080313749-A1 Binding Compounds, Immunogenic Compounds and Peptidomimetics PEPSCAN SYSTEMS B.V. (NL) 2008-12-18 US claimed
WO-2008013454-A2 IMMUNOGENIC COMPOUNDS AND PROTEIN MIMICS PEPSCAN SYSTEMS B.V. (NL) 2008-01-31 WO claimed
EP-1844337-A1 BINDING COMPOUNDS, IMMUNOGENIC COMPOUNDS AND PEPTIDOMIMETICS PEPSCAN SYSTEMS B.V. (NL) 2007-10-17 EP claimed
WO-2006078161-A1 BINDING COMPOUNDS, IMMUNOGENIC COMPOUNDS AND PEPTIDOMIMETICS PEPSCAN SYSTEMS B.V. (NL) 2006-07-27 WO claimed
US-20060073518-A1 Method for selecting a candidate drug compound PEPSCAN SYSTEMS B. V. (NL) 2006-04-06 US claimed
EP-1597585-A2 METHOD FOR SELECTING A CANDIDATE DRUG COMPOUND PEPSCAN SYSTEMS B.V. (NL) 2005-11-23 EP claimed
WO-2004077062-A2 METHOD FOR SELECTING A CANDIDATE DRUG COMPOUND PEPSCAN SYSTEMS B.V. (NL) 2004-09-10 WO claimed
EP-1452868-A2 Method for selecting a candidate drug compound PEPSCAN SYSTEMS B.V. (NL) 2004-09-01 EP claimed
US-20260137791-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 Bicyclerd Limited (GB) 2026-05-21 US disclosed
US-4351924-A USING A REACTION PRODUCT OF AN ORGANO ALKALI METAL ACETAL OR KETAL AND 1,1-DIPHENYLETHYLENE; AUTOMOBILE POWDER COATINGS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1982-09-28 US disclosed
US-3959232-A Polyamide from hexahydrobenzodipyrrole THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080313749-A1 Binding Compounds, Immunogenic Compounds and Peptidomimetics CXCL10, CCL2, CD74 TRPA1 174/4885ALDH1A1 4812/4885TSHR 3066/4885
US-20260137791-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 PDCD1LG2, CD274, PDCD1 TRPA1 4657/4885ALDH1A1 3312/4885TSHR 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.